Turton, Samuel
Myers, James FM
Mick, Inge
Colasanti, Alessandro
Venkataraman, Ashwin
Durant, Claire
Waldman, Adam
Brailsford, Alan
Parkin, Mark C
Dawe, Gemma
Rabiner, Eugenii A http://orcid.org/0000-0003-3612-6687
Gunn, Roger N http://orcid.org/0000-0003-1181-5769
Lightman, Stafford L
Nutt, David J http://orcid.org/0000-0002-1286-1401
Lingford-Hughes, Anne
Funding for this research was provided by:
Medical Research Council (G1002226)
Article History
Received: 21 September 2017
Revised: 9 May 2018
Accepted: 14 May 2018
First Online: 25 June 2018
Compliance with ethical standards
:
: Professor Lingford-Hughes has received honoraria paid into her institutional funds for speaking and chairing engagements from Lundbeck, Lundbeck Institute UK and Janssen-Cilag. She has received research support from Lundbeck and has been consulted by but received no monies from Britannia Pharmaceuticals. Professor Nutt has consulted for, or received speaker’s fees, or travel or grant support from the following companies with an interest in the treatment of addiction: RB pharmaceuticals, Lundbeck, GSK, Pfizer, D&A Pharma, Nalpharm, Opiant Pharmaceutical and Alkermes. Professor Gunn is a consultant for Abbvie and Cerveau. Dr Rabiner is a consultant for Opiant Pharmaceutical, AbbVie, Teva, and a shareholder in GSK. Professor Waldman has received honoraria from Bayer, Novartis, and GSK, and has been a consultant for Bayer.